Jereme M. Sylvain Sells 2,090 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

DexCom Stock Up 1.4 %

Shares of DXCM traded up $1.19 during mid-day trading on Thursday, hitting $87.62. 2,123,429 shares of the company’s stock were exchanged, compared to its average volume of 3,649,357. The company has a 50-day simple moving average of $80.22 and a 200 day simple moving average of $76.59. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The company has a market cap of $34.22 billion, a PE ratio of 52.47, a P/E/G ratio of 2.23 and a beta of 1.12. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of analyst reports. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and increased their price target for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Raymond James decreased their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. Wells Fargo & Company upped their price target on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Finally, Royal Bank of Canada reduced their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Five investment analysts have rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $99.29.

Institutional Investors Weigh In On DexCom

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Creative Planning raised its holdings in DexCom by 4.9% during the second quarter. Creative Planning now owns 48,693 shares of the medical device company’s stock worth $5,521,000 after acquiring an additional 2,271 shares in the last quarter. NewEdge Advisors LLC raised its stake in shares of DexCom by 18.3% during the 2nd quarter. NewEdge Advisors LLC now owns 9,020 shares of the medical device company’s stock worth $1,023,000 after purchasing an additional 1,393 shares in the last quarter. B. Riley Wealth Advisors Inc. boosted its holdings in shares of DexCom by 4.3% in the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 3,928 shares of the medical device company’s stock valued at $445,000 after buying an additional 162 shares during the last quarter. New Wave Wealth Advisors LLC acquired a new stake in shares of DexCom in the 2nd quarter valued at approximately $253,000. Finally, Brown Financial Advisors acquired a new position in DexCom during the second quarter worth $1,236,000. 97.75% of the stock is owned by institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.